Fennec Pharmaceuticals Released Topline Results From Phase 2/3 STS-J01 Trial Of Pedmark (Sodium Thiosulfate Injection) For The Reduction Of Cisplatin-induced Ototoxicity In Pediatric And Adolescent And Young Adult Patients With Non-metastatic Solid Tumors In Japan
Benzinga Newsdesk 11 months ago
BiotechHealth CareGeneral
Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK when Compared with Historically Reported Rates of Hearing Loss in
- Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cisplatin Alone (16-24% versus 56-63%, Respectively).
- PEDMARK Showed No Interference with Cisplatin Antitumor Activity as Evidenced by an Approximate 95% Clinical Response Rate.
- The Company Plans to Pursue Registration and is Exploring Partnering or Licensing Opportunities for PEDMARK® in Japan Based Upon These Results